Hebei Senlang Biotech

China

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
4 in Phase 2
3 in Phase 1
Next date
Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells, Phase 1 trial completes
Drugs
7
in active trials · 10 in all
Trials
6 active
10 since 2021

Drugs7

DrugHow it worksPartnerStageNext dateDetails
—
Phase 2 31 Mar 2027Phase 2 trial completes
—
Phase 1/2 18 Aug 2027Phase 1/2 trial completes
—
Phase 1/2 1 Feb 2028Phase 1/2 trial completes
—
Phase 2 —
—
Phase 1 30 Mar 2027Phase 1 trial completes
In vivo CLL-1 CAR-T, lentiviral
Phase 1 31 Oct 2028Phase 1 trial completes
SENL101not checked
—
Phase 1 —

About

No active trial
Autologous aPD-L1 armored anti-CD22 CAR T cells, Autologous CD19-targeting CAR T cells, CD7 CAR-T
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021

Follow Hebei Senlang Biotech

Following is part of Solo: you see every change to Hebei Senlang Biotech the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in